ARVN002

ARVN002 (atropine ophthalmic solution), known as MicroPine in US, is developed by Eyenovia, Inc. (NASDAQ: EYEN) for progressive myopia, a back-of-the-eye condition commonly known as nearsightedness. ARVN002 is designed based on Eyenovia's Optejet® microdose formulation and delivery platform using its patented high-precision piezo-print technology known as MAP™ (microdose array print) to deliver 6-8 μL of drug, consistent with the capacity of the tear film of the eye. Microdose administration of ARVN002 is anticipated to result in low systemic and ocular drug exposure while improving comfort and ease-of-use in children. A recent therapeutic evidence assessment and review by the American Academy of Ophthalmology indicates Level 1 (highest) evidence of efficacyfor the role of low dose atropine for progressive myopia (Ophthalmology2017;124:1857-1866; Ophthalmology 2016; 123(2) 391:399).